Advanced Filters
noise

Seol, Korea, Republic of Clinical Trials

A listing of Seol, Korea, Republic of clinical trials actively recruiting patients volunteers.

Found 1,034 clinical trials

A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma

This study is to evaluate the safety, tolerability, efficacy and immunogenicity of RZ-001 in combination with Valganciclovir (VGCV) and Atezolizumab/Bevacizumab when given to subjects with human telomerase reverse transcriptase (hTERT)-positive HCC.

18 years of age All Phase 1/2
M Myung-Ju Ahn, M.D.

Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma

Primary Objective: Major pathologic response rate defined by ≤ 10% of tumor composed of viable tumor 2. Secondary Objectives: Complete resection rate Response rate to neoadjuvant therapy according to RECIST 1.1 Downstaging at pathologic staging compared to clinical staging performed at study entry Distant metastasis free survival (DMFS) rate at …

19 years of age All Phase 2
E EunJoo Park

AZD6738 Plus Durvalumab in Biliary Tract Cancer

This trial will enroll advanced biliary tract cancer patients who have been previously treated with immunotherapy in either the 2nd or 3rd line. Patients will be treated with AZD6738 and Durvalumab combination.

20 years of age All Phase 2

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 in Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent over a range of advanced and/or metastatic solid tumors.

18 years of age All Phase 1/2
N NA NA

Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)

In this study, we prospectively analyzed molecular subtyping through the PAM 50 test in HER2-negative (IHC1+ or 2+ (FISH/SISH-)) breast cancer patients. A phase 2 single arm study was designed to determine whether the addition of HER2-targeted treatment with treatment increases the pathologic remission rate.

19 years of age All Phase 2
J Jung-Yun Lee

Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)

phase 2 clinical trial to confirm the pathological complete response rate of PD-1 blocker use in patients with Mismatch Repair Deficiency(MMRd) endometrial cancer that can be completely resected surgically.

20 years of age Female Phase 2
S Seung-Bum Ryoo, MD, PhD

The Safety and Efficacy of Transanal Irrigation in Patients With Sleep Disturbance From Low Anterior Resection Syndrome After Rectal Cancer Surgery (TraLARS)

The preservation surgery of the anal sphincter muscle has become the standard procedure in the treatment of rectal cancer and, thanks to advancements in surgical techniques, can now be performed for tumors located closer to the anus. This method allows patients to avoid a permanent artificial anus, maintaining continuity of …

19 - 80 years of age All Phase N/A
H Hyung-Don Kim, MD, PhD

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

The purpose of this study is to evaluate the efficacy and safety of rivoceranib and paclitaxel combination therapy in patients with P-glycoprotein overexpressing GIST who failed standard treatment with imatinib, sunitinib, and regorafenib.

20 years of age All Phase 2
S Sunmi Song, PhD

Development of a Healthcare Service Platform for Successful Aging

The goal of this living-lab clinical trial is to test the effectiveness of digital health monitoring and feedback platform for community dwelling older adults. The main questions it aims to answer are: Identify digital sensing variables that are predictive of mental and physical health declines and health emergencies of older …

65 years of age All Phase N/A

Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance

This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance.

18 years of age Female Phase 2

Simplify language using AI